NDA 206333 · Abbvie
Kybella
Deoxycholic Acid · Subcutaneous · Cytolytic Agent
NovelLast checked: Nov 19, 2026Latest source record: Sep 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Apr 29, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
205
52 Phase 3, 21 recruiting
FAERS reports
2,334
189 serious, 10 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 11, 2026.
KYBELLA ® is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. Limitations of U se KYBELLA is not approved for the treatment of subcutaneous fat outside the submental region, and such use is not recommended [see Warnings and Precautions ( 5.5 )]. KYBELLA is a cytolytic drug indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. ( 1 ) Limit ation s of Use KYBELLA is not approved for the treatment of subcutaneous fat outside the submental region, and such use is not recommended. ( 1 , 5.5 )
Mechanism: KYBELLA is a cytolytic drug, which when injected into submental fat - in patients with moderate to severe convexity or fullness associated with submental fat - physically destroys the cell membrane causing lysis.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 29, 2015 Original approval · Type 1 - New Molecular Entity NovelLabelReviewSummary Review
1 products under this application
- KYBELLA · DEOXYCHOLIC ACID 20MG/2ML (10MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Deoxycholic Acid" as an intervention, any sponsor and status, largest first.
- Amphotericin B Treatment in Visceral LeishmaniasisPivotal-lookingCompleted
Banaras Hindu UniversityAcademic, hospital or other
NCT00310505 · 1,500 participants · Start Jan 2003
Drug: Amphotericin B deoxycholate given as daily administration · For: Visceral Leishmaniasis
Sites: Muzaffarpur, India
- Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by StatinPivotal-lookingStatus unknown
First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
NCT05500937 · 1,000 participants (planned) · Start Mar 1, 2021 · Primary completion Dec 31, 2023
Drug: UDCA · For: Diabetes Mellitus
Sites: Xi’an, China
- MITE in the Treatment of Dyspepsia After CholecystectomyPivotal-lookingStatus unknown
Xinhua Hospital, Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT04786795 · 990 participants (planned) · Start Mar 1, 2021 · Primary completion Feb 1, 2022
Drug: Compound Azintamide Enteric-coated Tablets; Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets · For: Patients With Dyspeptic Symptoms After Cholecystectomy
- Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral LeishmaniasisPivotal-lookingCompleted
Drugs for Neglected DiseasesAcademic, hospital or other
NCT00696969 · 634 participants · Start Jun 2008 · Primary completion Jan 2010
Drug: Amphotericin B Deoxycholate; Ambisome + Miltefosine and 2 more · For: Visceral Leishmaniasis
Sites: Muzaffarpur, India; Patna, India
- Combination Therapy in Indian Visceral LeishmaniasisPivotal-lookingCompleted
Banaras Hindu UniversityAcademic, hospital or other
NCT00523965 · 624 participants (planned) · Start Sep 2007 · Primary completion Aug 2009
Drug: amphotericin B deoxycholate; Liposomal Amphotericin B with Miltefosine and 2 more · For: Leishmaniasis, Visceral
Sites: Muzaffarpur, India
- Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis CPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT00200343 · 596 participants · Start Jul 2002
Drug: Ursodeoxycholic acid 150mg / day; Ursodeoxycholic acid 600mg / day and 1 more · For: Chronic Hepatitis C
Sites: Hongo, Bunkyo-ku, Tokyo, Japan
- Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental AreaPivotal-lookingCompleted
Kythera BiopharmaceuticalsIndustry
NCT01546142 · 516 participants · Start Mar 2012 · Primary completion May 2013
Drug: Deoxycholic acid injection; Placebo · For: Moderate or Severe Submental Fullness
Sites: Little Rock, Arkansas; Beverly Hills, California; Los Angeles, California · 35 sites in all
- Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental AreaPivotal-lookingCompleted
Kythera BiopharmaceuticalsIndustry
NCT01542034 · 506 participants · Start Feb 2012 · Primary completion May 2013
Drug: Deoxycholic acid injection; Placebo · For: Moderate or Severe Submental Fullness
Sites: Birmingham, Alabama; Beverly Hills, California; Irvine, California · 36 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective327
- injection site swelling305
- off label use287
- swelling262
- injection site pain191
- facial paresis130
- injection site nodule123
- nerve injury115
- hypoaesthesia110
- injection site mass104
- injection site induration86
- contusion85
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 39 |
| 2016 | 354 |
| 2017 | 212 |
| 2018 | 392 |
| 2019 | 314 |
| 2020 | 219 |
| 2021 | 219 |
| 2022 | 203 |
| 2023 | 208 |
| 2024 | 71 |
| 2025 | 73 |
| 2026 | 27 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Exercise Training Independent of Intensity Lowers Plasma Bile Acids in Prediabetes.
Malin SK, Syeda USA · Med Sci Sports Exerc 2024 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review.
Wang C, Gu Y, Chu Q, et al. · Microbiol Res 2024 · Systematic Review
- Efficacy, safety, and potential industry bias in using deoxycholic acid for submental fat reduction ߜ A systematic review and meta-analysis of randomized clinical trials.
Inocêncio GSG, Meneses-Santos D, Costa MDMA, et al. · Clinics (Sao Paulo) 2023 · Meta-Analysis, Systematic Review
- Safety and Efficacy of Deoxycholic Acid for Reduction of Upper Inner Thigh Fat.
Yuan J, Shafiq F, Ortiz A · J Drugs Dermatol 2022 · Clinical Trial, Phase I
- Curcumin supplementation alleviates hepatic fat content associated with modulation of gut microbiota-dependent bile acid metabolism in patients with nonalcoholic simple fatty liver disease: a randomized controlled trial.
He Y, Chen X, Li Y, et al. · Am J Clin Nutr 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy and safety of Tanreqing injection for cough caused by acute trachea-bronchitis disease: A systematic review and meta-analysis of randomized controlled trials.
Ma N, Pan B, Ge L, et al. · J Ethnopharmacol 2024 · Meta-Analysis, Systematic Review
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.